多发性骨髓瘤疾病全周期健康管理
Full-cycle Health Management of Multiple Myeloma
查看参考文献44篇
|
文摘
|
多发性骨髓瘤是以克隆性浆细胞增殖为特征的血液系统肿瘤。伴随新药和免疫治疗的发展,多发性骨髓瘤预后显著改善,半数以上患者将长期生存10年以上;因此,其疾病管理模式亟待优化。健康管理是慢性病防治的有效方法;疾病全周期健康管理理念要求健康管理应从疾病前期到终末期全过程实施。把全周期管理理念植入到多发性骨髓瘤的健康管理实践中,将有力且高效地指导并规范骨髓瘤疾病全周期健康管理工作切实推进。本文就多发性骨髓瘤疾病的全周期概念以及相应的健康管理内容进行综述。 |
|
其他语种文摘
|
Multiple myeloma is a hematologic tumor characterized by clonal proliferation of plasma cells. The development of novel agents and immunotherapy have substantially improved the prognosis of multiple myeloma, with an expectable median survival beyond ten years. Therefore,there is an urgent need to improve the management of this disease. Health management is effective in controlling chronic diseases and full-cycle management should be implemented from the early to the end stage of the disease. Implanting the full-cycle concept into the health management of multiple myeloma will guide and standardize the advances in this field. This review focuses on the full-cycle concept of multiple myeloma and the corresponding application of health management at each stage of the cycle. |
|
来源
|
中国医学科学院学报
,2022,44(4):673-677 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.13467
|
|
关键词
|
多发性骨髓瘤
;
全周期
;
健康管理
;
意义未明的单克隆免疫球蛋白血症
;
冒烟型骨髓瘤
|
|
地址
|
四川大学华西医院血液内科血液病研究所, 成都, 610041
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1000-503X |
|
学科
|
内科学 |
|
基金
|
国家自然科学基金
;
四川省自然科学基金
;
四川省大学生创新创业训练计划
|
|
文献收藏号
|
CSCD:7291129
|
参考文献 共
44
共3页
|
|
1.
Liu J. Incidence and mortality of multiple myeloma in China,2006-2016: an analysis of the Global Burden of Disease Study 2016.
J Hematol Oncol,2019,12(1):136
|
CSCD被引
12
次
|
|
|
|
|
2.
Gay F. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
Haematologica,2018,103(2):197-211
|
CSCD被引
1
次
|
|
|
|
|
3.
Joseph N S. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma.
J Clin Oncol,2020,38(17):1928-1937
|
CSCD被引
12
次
|
|
|
|
|
4.
Zhou M. Mortality,morbidity,and risk factors in China and its provinces,1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet,2019,394(10204):1145-1158
|
CSCD被引
847
次
|
|
|
|
|
5.
国家卫生和计划生育委员会.
《"健康中国2030"规划纲要》辅导读本,2017
|
CSCD被引
3
次
|
|
|
|
|
6.
中华人民共和国国务院. 中国防治慢性病中长期规划(2017-2025年).
中国实用乡村医生杂志,2017,24(11):6-11
|
CSCD被引
13
次
|
|
|
|
|
7.
中华医学会健康管理学分会. 健康管理概念与学科体系的中国专家初步共识.
中华健康管理学杂志,2009,3(3):141-147
|
CSCD被引
41
次
|
|
|
|
|
8.
黎立喜. 乳腺癌全方位和全周期的健康管理模式.
中国医学前沿杂志(电子版),2020,12(3):前插1,1-5
|
CSCD被引
3
次
|
|
|
|
|
9.
Han J H. Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China.
Blood Cancer J,2020,10(3):34
|
CSCD被引
3
次
|
|
|
|
|
10.
Kyle R A. Prevalence of monoclonal gammopathy of undetermined significance.
N Engl J Med,2006,354(13):1362-1369
|
CSCD被引
14
次
|
|
|
|
|
11.
Atkin C. The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions.
Br J Haematol,2020,189(6):1127-1135
|
CSCD被引
1
次
|
|
|
|
|
12.
Iwanaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52, 802 persons in Nagasaki City,Japan.
Mayo Clin Proc,2007,82(12):1474-1479
|
CSCD被引
3
次
|
|
|
|
|
13.
Ho M. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Leukemia,2020
|
CSCD被引
1
次
|
|
|
|
|
14.
Kyle R A. Long-term followup of monoclonal gammopathy of undetermined significance.
N Engl J Med,2018,378(3):241-249
|
CSCD被引
7
次
|
|
|
|
|
15.
Kyle R A. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
N Engl J Med,2007,356(25):2582-2590
|
CSCD被引
13
次
|
|
|
|
|
16.
Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
Blood,2009,113(22):5412-5417
|
CSCD被引
13
次
|
|
|
|
|
17.
Landgren O. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Bone Marrow Transplant,2016,51(12):1565-1568
|
CSCD被引
7
次
|
|
|
|
|
18.
中国医师协会血液科医师分会. 中国多发性骨髓瘤诊治指南(2022年修订).
中华内科杂志,2022,61(5):480-487
|
CSCD被引
75
次
|
|
|
|
|
19.
Robak P. Drug resistance in multiple myeloma.
Cancer Treat Rev,2018,70:199-208
|
CSCD被引
7
次
|
|
|
|
|
20.
Chakraborty R. Treatment and disease-related complications in multiple myeloma: implications for survivorship.
Am J Hematol,2020,95(6):672-690
|
CSCD被引
7
次
|
|
|
|
|
了解气象卫星更多信息，请访问